These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 31051328)

  • 21. Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.
    Michel C; Burchert A; Hochhaus A; Saussele S; Neubauer A; Lauseker M; Krause SW; Kolb HJ; Hossfeld DK; Nerl C; Baerlocher GM; Heim D; Brümmendorf TH; Fabarius A; Haferlach C; Schlegelberger B; Balleisen L; Goebeler ME; Hänel M; Ho A; Dengler J; Falge C; Möhle R; Kremers S; Kneba M; Stegelmann F; Köhne CH; Lindemann HW; Waller CF; Spiekermann K; Berdel WE; Müller L; Edinger M; Mayer J; Beelen DW; Bentz M; Link H; Hertenstein B; Fuchs R; Wernli M; Schlegel F; Schlag R; de Wit M; Trümper L; Hebart H; Hahn M; Thomalla J; Scheid C; Schafhausen P; Verbeek W; Eckart MJ; Gassmann W; Schenk M; Brossart P; Wündisch T; Geer T; Bildat S; Schäfer E; Hasford J; Hehlmann R; Pfirrmann M
    Haematologica; 2019 May; 104(5):955-962. PubMed ID: 30514803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Analysis of efficacy and related factors in 85 chronic myeloid leukemia patients treated with imatinib mesylate].
    Zhou KS; Wang YY; Zhao YZ; Yi SH; Qian LS; Wang GR; Yu Z; Wang Y; Wang JX; Qiu LG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):208-12. PubMed ID: 20137149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib.
    Pfirrmann M; Evtimova D; Saussele S; Castagnetti F; Cervantes F; Janssen J; Hoffmann VS; Gugliotta G; Hehlmann R; Hochhaus A; Hasford J; Baccarani M
    J Cancer Res Clin Oncol; 2017 May; 143(5):843-850. PubMed ID: 28083711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
    Cohen MH; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution Experience.
    Dybko J; Jaźwiec B; Haus O; Urbaniak-Kujda D; Kapelko-Słowik K; Wróbel T; Lonc T; Sawicki M; Mędraś E; Kaczmar-Dybko A; Kuliczkowski K
    Dis Markers; 2016; 2016():7531472. PubMed ID: 27818567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival.
    Breccia M; Luciano L; Latagliata R; Castagnetti F; Ferrero D; Cavazzini F; Trawinska MM; Annunziata M; Stagno F; Tiribelli M; Binotto G; Crisà E; Musto P; Gozzini A; Cavalli L; Montefusco E; Iurlo A; Russo S; Cedrone M; Rossi AR; Pregno P; Endri M; Spadea A; Molica M; Giglio G; Celesti F; Sorà F; Storti S; D'Addosio A; Cambrin GR; Isidori A; Sica S; Abruzzese E; Speccha G; Rosti G; Alimena G
    Leuk Res; 2014 Oct; 38(10):1173-6. PubMed ID: 25047978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Impact of age on the clinical response of patients with CML treated with imatinib].
    Bělohlávková P; Voglová J; Radocha J; Žák P
    Vnitr Lek; 2015 Sep; 61(9):785-6, 788-91. PubMed ID: 26465277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis.
    Dalziel K; Round A; Stein K; Garside R; Price A
    Health Technol Assess; 2004 Jul; 8(28):iii, 1-120. PubMed ID: 15245690
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial.
    Suttorp M; Schulze P; Glauche I; Göhring G; von Neuhoff N; Metzler M; Sedlacek P; de Bont ESJM; Balduzzi A; Lausen B; Aleinikova O; Sufliarska S; Henze G; Strauss G; Eggert A; Kremens B; Groll AH; Berthold F; Klein C; Groß-Wieltsch U; Sykora KW; Borkhardt A; Kulozik AE; Schrappe M; Nowasz C; Krumbholz M; Tauer JT; Claviez A; Harbott J; Kreipe HH; Schlegelberger B; Thiede C
    Leukemia; 2018 Jul; 32(7):1657-1669. PubMed ID: 29925908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia.
    Tanrikulu Simsek E; Eskazan AE; Cengiz M; Ar MC; Ekizoglu S; Salihoglu A; Gulturk E; Elverdi T; Ongoren Aydin S; Senem Demiroz A; Buyru AN; Baslar Z; Ozbek U; Ferhanoglu B; Aydin Y; Tuzuner N; Soysal T
    J Clin Pathol; 2016 Sep; 69(9):810-6. PubMed ID: 26811428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
    Lejniece S; Udre I; Rivkina A
    Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A significant proportion of patients with chronic myeloid leukemia and suboptimal response according to European Leukemia Net criteria have excellent prognosis without treatment change.
    Rohon P; Faber E; Divoka M; Rozmanova S; Friedecky D; Jarosova M; Indrak K
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2013 Jun; 157(2):181-8. PubMed ID: 22660209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
    Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic phase chronic myeloid leukemia: response of imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic response.
    Usman M; Syed NN; Kakepoto GN; Adil SN; Khurshid M
    J Assoc Physicians India; 2007 Feb; 55():103-7. PubMed ID: 17571738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of imatinib mesylate in elderly patients in Northern Ireland: evidence of comparable haematological and molecular responses to younger patients.
    Sheehy OM; Irvine AE; Cuthbert RJ; Humphreys MW; McMullin MF
    Hematology; 2008 Jun; 13(3):133-6. PubMed ID: 18702869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia.
    Islamagic E; Hasic A; Kurtovic S; Suljovic Hadzimesic E; Mehinovic L; Kozaric M; Kurtovic-Kozaric A
    Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):238-240. PubMed ID: 28283298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of the BCR-ABL1 fusion transcripts on different responses to Imatinib and disease recurrence in Iranian patients with Chronic Myeloid Leukemia.
    Rostami G; Hamid M; Jalaeikhoo H
    Gene; 2017 Sep; 627():202-206. PubMed ID: 28627443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful use of National Cancer Registry data to monitor the effective use of imatinib for treating chronic myeloid leukaemia.
    Shepherd P; Dhanapala C; Maguire C; White J; Drummond M; Holyoake T; Johnson PR
    Scott Med J; 2008 Aug; 53(3):8-12. PubMed ID: 18780518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy.
    Haaß W; Kleiner H; Weiß C; Haferlach C; Schlegelberger B; Müller MC; Hehlmann R; Hofmann WK; Fabarius A; Seifarth W; ;
    PLoS One; 2015; 10(6):e0129648. PubMed ID: 26087013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low ABCB1 and high OCT1 levels play a favorable role in the molecular response to imatinib in CML patients in the community clinical practice.
    da Cunha Vasconcelos F; Mauricio Scheiner MA; Moellman-Coelho A; Mencalha AL; Renault IZ; Rumjanek VM; Maia RC
    Leuk Res; 2016 Dec; 51():3-10. PubMed ID: 27770655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.